Donner B, Zenz M, Strumpf M, Raber M
Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Bergmannsheil, Bochum, Germany.
J Pain Symptom Manage. 1998 Mar;15(3):168-75. doi: 10.1016/s0885-3924(97)00361-8.
The long-term therapy of 51 patients using transdermal fentanyl was evaluated. The transdermal therapy was performed for 158 days (range, 15-855 days). The need for increasing dosages of transdermal fentanyl was caused by the progression of the underlying cancer disease (mean initial dose, 69.5 micrograms fentanyl/hr; mean final dose, 167.7 micrograms fentanyl/hr). The transdermal system was changed every third day. Application intervals had to be shortened in 23.5% of the patients. Pain reduction was good throughout the study. Severe side effects did not occur. Constipation and the need for laxatives occurred less frequently than with previously administered oral morphine. Skin tolerance of the transdermal system was good. The treatment of cancer pain with transdermal fentanyl can be performed as a long-term therapy and result in good pain relief. Considering its specific pharmacokinetic properties, it is an alternative medication on step III of the World Health Organization's guidelines for cancer pain management.
对51例使用透皮芬太尼进行长期治疗的患者进行了评估。透皮治疗持续了158天（范围为15 - 855天）。增加透皮芬太尼剂量的需求是由潜在癌症疾病的进展引起的（平均初始剂量为69.5微克芬太尼/小时；平均最终剂量为167.7微克芬太尼/小时）。每三天更换一次透皮系统。23.5%的患者不得不缩短用药间隔。在整个研究过程中疼痛缓解良好。未出现严重副作用。便秘和使用泻药的需求比之前口服吗啡时更少见。透皮系统的皮肤耐受性良好。透皮芬太尼治疗癌痛可作为一种长期治疗方法，能有效缓解疼痛。考虑到其特定的药代动力学特性，它是世界卫生组织癌症疼痛管理指南第三步中的一种替代药物。
